COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
COSCIENS Biopharma Inc. (CSCI)
Company Research
Source: GlobeNewswire
TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today provided an update on the progress of its merger integration with Ceapro Inc. (“Ceapro”), including planned changes to its management team and advancements across its current business. “With the initial integration efforts now well underway, I believe now is the ideal time for the next generation of leaders to make their mark on the future of COSCIENS. To that end, with my full support, our Board has engaged an executive recruiting firm to identify the next President and CEO of COSCIENS. I remain fully committed to lead and support COSCIENS while that search is underway and will provide whatever support my successor needs through the transition,” stated Gilles Gagnon, M.Sc., MBA, President
Show less
Read more
Impact Snapshot
Event Time:
CSCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSCI alerts
High impacting COSCIENS Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
CSCI
News
- COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development ProgramsGlobeNewswire
- COSCIENS Biopharma Announces Change to Board of DirectorsGlobeNewswire
- COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director [Yahoo! Finance]Yahoo! Finance
- COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director [Financial Post (Toronto, Ontario, Canada)]Financial Post
CSCI
Sec Filings
- 11/12/24 - Form 6-K
- 11/12/24 - Form 6-K
- 10/8/24 - Form 6-K
- CSCI's page on the SEC website